Ribozymal nucleic acid

Details Ribozymal nucleic acid Ribozymal nucleic acid

2005-07-12

2005-07-12

LeGuyader, John L. (Department: 1635)

Chemistry: molecular biology and microbiology

Vector, per se

C435S091100, C435S091310, C435S091400, C536S023100, C536S024500

Reexamination Certificate

active

06916653

ABSTRACT:
A vector system which can be incorporated in liposomes, comprising at least one DNA vector, the vector or vectors containing a target-cleaving hammerhead ribozymal DNA sequence under control of a promoter effective in human cells and which, upon transcription to RNA will cleave the mRNA transcribed from a target gene encoding the CCR5 or CXCR4 protein.Preferably the ribozymal DNA contains a first recognition sequence (5′ to 3′):tagattg or ctcact, respectively for CCR5 or CXCR4 and downstream thereof a second recognition sequenceacttg or acgttgt respectively for CCR5 or CXCR4.

REFERENCES:
patent: 4987071 (1991-01-01), Cech et al.
patent: 5037746 (1991-08-01), Cech et al.
patent: 5093246 (1992-03-01), Cech et al.
patent: 5116742 (1992-05-01), Cech et al.
patent: 5354855 (1994-10-01), Cech et al.
patent: 5591610 (1997-01-01), Cech et al.
patent: 5594122 (1997-01-01), Friesen
patent: 5910628 (1999-06-01), Miller et al.
patent: 5939538 (1999-08-01), Leavitt et al.
patent: 6025154 (2000-02-01), Li et al.
patent: 291533 (1995-10-01), None
patent: 97/45543 (1997-04-01), None
patent: WO 97/17433 (1997-05-01), None
patent: 97/28258 (1997-07-01), None
patent: WO 97/41243 (1997-11-01), None
patent: WO 97/44055 (1997-11-01), None
patent: WO 97/45543 (1997-12-01), None
patent: WO 98/05798 (1998-02-01), None
patent: WO 98/17308 (1998-04-01), None
patent: WO 98/34945 (1998-08-01), None
Graham Simmons et al., Science 276, Apr. 1997, pp. 276-279, “Potent Inhibition of HIV-1 Infectivity in Macrophages and Lymphocytes by a Novel CCR5 Antagonist”.
Christophe Combadiere et al., The Journal of Biological Chemistry 270, Jul. 1995, pp. 16491-16494, “Cloning and Functional Expression of a Human Eosinophil CC Chemokine Receptor”.
Manuel A González et al., Biochemical and Biophysical Research Communications 251, pp. 592-596 (1998), “A Hammerhead Ribozyme Targeted to the Human Chemokine Receptor CCR5”.
Bartolome Federsppiel et al., Genomics 16, pp. 707-712 (1993), “Molecular Cloning of the cDNA and Chromosomal Localization of the Gene for a Putative Seven-Transmembrane Segment (7-TMS) Receptor Isolated from Human Spleen”.
Ritu Goila et al., FEBS Letters 436 (1998) pp. 233-238, “Sequence specific cleavage of the HIV-1 coreceptor CCR5 gene by a hammer-head ribozyme and a DNA-enzyme: inhibition of the coreceptor function by DNA-enzyme”.
Nava Sarver et al., Science 247, Mar. 1990, pp. 1222-1225, “Ribozymes as Potential Anti-HIV-1 Therapeutic Agents”.
D G Kim et al., Molecular and Cellular Biology 12, 1992, pp. 3636-3643, “Construction of a Bifunctional mRNA in the Mouse by Using the Internal Ribosomal Entry Site of the Encephalomyocarditis Virus”.
M Brisson et al., Gene Therapy 6, 1999, pp. 263-270, “A novel T7 RNA polymerase autogene for efficient cytoplasmic expression of target genes”.
Larry A Couture et al., TIG 12, Dec. 1996, “Anti-gene therapy: the use of ribozymes to inhibit gene function”.
William G Scott et al., TIBS 21, Jun. 1996, pp. 220-224, “Ribozymes: structure and mechanism in RNA catalysis”.
John J Rossi et al., Aids Research and Human Retroviruses 8, 1992, pp. 183-189, “Ribozymes as Anti-HIV-1 Therapeutic Agents: Principles, Applications, and Problems”.
John M Burke, Nature Biotechnology 15, May 1997, pp. 414-415, “Clearing the way for ribozymes”.
Andy Coghlan, New Scientist 152 N° 2059, Dec. 1996, p. 24, “Can gene scissors chop up HIV?”.
Thomas R Cech et al., Nature 372, Nov. 3, 1994, pp. 39-40, “Hammerhead nailed down”.
Scientific American, Sep. 1997, pp. 28-35, “In Search of AIDS-Resistance Genes”, Stephen J O'Brien et al.
C Mark Hill et al., Nature 382, Aug. 22, 1996, pp. 668-669, “Natural resistance to HIV?”.
Drew Weissman et al., Nature 389, Oct. 30, 1997, pp. 981-985, Macrophage-tropic HIV and SIV envelope proteins induce a signal through the CCR5 chemokine receptor.
Jon Cohen, Science 275, Feb. 28, 1997, pp. 1261-1264, “Exploiting the HIV-Chemokine Nexus”.
Alex Eccleston, Nature Biotechnology 15 (8), Aug. 1997, pp. 709, 711, “Chemokine inhibitors for HIV”.
Ruth I Connor et al., J Exp. Med., 185 N° 4, Feb. 17, 1997, pp. 621-628, “Change in Coreceptor Use Correlates with Disease Progression in HIV-1 Infected Individuals”.
No author stated, Antiviral Agents Bulletin, 10 N° 9, Sep. 1997, pp. 261-262, “Trojan Horse Virus Controls HIV in vitro”.
John J Rossi et al., BioDrugs 1, Jan. 1998, pp. 1-10, “Therapeutic Ribozymes: Principles and Applications”.
Benjamin J Doranz et al., Cell 85, Jun. 28, 1996, pp. 1149-1158, “A Dual-Tropic Primary HIV-1 Isolate That Uses Fusin and the β-Chemokine Receptors CKR-5, CKR-3 and CKR-2b as Fusion Cofactors”.
Bharat M Chowrira et al., Journal of Biological Chemistry, 269 N° 41, Oct. 14, 1994, pp. 25856-25864, “In vitro and in Vivo Comparison of Hammerhead, Hairpin, and Hepatitis Delta Virus Self-processing Ribozyme Cassettes”.
No author stated, Nature Biotechnology 16, Jul. 1998, p. 606, “Piggyback ribozymes”.
Sun K Jang et al., Journal of Virology 63, Apr. 1989, pp. 1651-1660, “Initiation of Protein Synthesis by Internal Entry of Ribosomes into the 5′ Nontranslated Region of Encephalomyocarditis Virus RNA In Vivo”.
R Tritz et al., AIDS Weekly Plus, May 19, 1997, p. 31, “Development of Novel anti-CCR5 Hairpin Ribozyme: Treatment for HIV Infections”.
Georges Herbein et al., Nature 395, Sep. 1998, pp. 189-194, “Apoptosis of CD8+Tcells is mediated by macrophages through interaction of HIV gp 120 with chemokine receptor CXCR4”.
James, W., Antiviral Chem. and Chemotherapy, vol. 2, No. 4, pp. 191-214.
Milner et al, Nature Biotech., vol. 15, pp. 537-541.
Branch, A., Trends in Bioch. Sci., vol. 23, pp. 45-50.
Friedmann, T., Scientific Amer., Jun. vol., pp. 96-101.
Crystal, R.G. Science, vol. 270, pp. 404-410.
Schofield et al, Brit. Med. Bull., vol. 51, No. 1, pp. 56-71.
Verma et al, Nature, vol. 389, pp. 239-242.
Crooke, S.T. Antisense Research and Application, Chapter 1, pp. 1-50. Publ. by Springer-Verlag.

Affiliated with

Also associated with

Rating

Ribozymal nucleic acid does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Ribozymal nucleic acid, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Ribozymal nucleic acid will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3384562